Testing a new stroke treatment using magnetic nanorobots
Steered t-PA Delivery for Thrombolysis Test Using Magnetic Swarming Nanorobots on Human Placenta as an ex Vivo Model of Human Cerebral Vascular System
This study is testing a new way to deliver a stroke treatment using tiny magnetic robots to see if it can work better and cause less damage to surrounding tissues.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 20 Years to 45 Years |
| Sex | Female |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 2 sites (Shatin, New Territories and 1 other locations) |
| Trial ID | NCT04644653 on ClinicalTrials.gov |
What this trial studies
This study investigates a novel approach to improve the delivery of tissue plasminogen activator (tPA) for treating thrombosis, particularly in ischemic stroke. By utilizing a magnetic nanorobotic system, the research aims to enhance the targeting accuracy of tPA, minimizing collateral damage to surrounding tissues. The study will use human placenta as an ex vivo model to simulate the human cerebral vascular system, allowing for a controlled environment to assess the effectiveness of this targeted thrombolysis method.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy pregnant women aged 20-45 who are giving childbirth and meet specific health criteria.
Not a fit: Patients with a history of stroke, vascular disease, diabetes, or other significant medical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and safer treatments for patients suffering from ischemic strokes and other thrombotic diseases.
How similar studies have performed: While this approach is innovative, similar studies using targeted drug delivery systems have shown promise, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy pregnant women at 20-45 years of age of any ethic origin, giving childbirth with natural delivery or caesarean sections after 37-42 weeks of gestation. * Healthy singleton pregnancy. * Participant able to give voluntary, written, informed consent to participate in the study. Exclusion Criteria: * Abnormal prenatal development (e.g intrauterine growth restriction) * Early preterm birth \< 37 weeks * Verbal Confirmation of hypercholesterolemia * Family history of stroke or vascular disease * Type I or Type II diabetes and gestational diabetes * Cancer, except skin cancers completely excised with no chemotherapy or radiation with a follow up that is negative. * Clinically significant abnormal laboratory results at screening. * Any other active or unstable medical condition. * History of liver disease. * History of hypertension (including pre-eclampsia)
Where this trial is running
Shatin, New Territories and 1 other locations
- Advanced Nanomaterials & Microrobotics Laboratory, Room 202, William M.W Mong Engineering Building, CUHK and Room 508, Li Ka Shing Medical Sciences Building, Prince of Wales Hospital — Shatin, New Territories, Hong Kong (Active_not_recruiting)
- Department of Obstetrics and Gynaecology, Prince of Wales Hospital — Shatin, New Territories, Hong Kong (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.